

# A world leader in allergy immunotherapy




**GAP results – 14 January 2016**

EVP Henrik Jacobi and VP Per Plotnikof



# GRAZAX<sup>®</sup> Asthma Prevention (GAP) trial


- First large, multinational placebo-controlled trial with Allergy Immunotherapy (GRAZAX<sup>®</sup>) in asthma prevention
  - 812 children (5-12 years) in 11 EU countries with a clinical history of grass pollen allergy but no signs of asthma
  - Screening phase to rule out asthma
  - Three-year treatment phase with daily intake of GRAZAX<sup>®</sup> tablets or placebo
  - Two-year follow-up phase to monitor effects after completion of treatment
- Objective: To investigate the effect of GRAZAX<sup>®</sup> vs. placebo on children's risk of developing asthma



# Top-line results

- The trial did not show an effect in terms of time to first diagnosis of reversible impairment of lung function.
- The trial demonstrated that GRAZAX<sup>®</sup> treatment significantly reduced the proportion of children experiencing asthma symptoms or using asthma medication. This effect sustained two years after end of treatment.
- Moreover, the trial confirmed that GRAZAX<sup>®</sup> treatment significantly reduced allergic rhinoconjunctivitis symptoms. This effect sustained two years after end of treatment.
- The disease-modifying effect of GRAZAX<sup>®</sup> was confirmed in children.


# Asthma symptoms or usage of asthma medication – by year



# Q&A session

## Forward-looking statements

This presentation contains forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are subject to risks and uncertainties as various factors, some of which are beyond ALK's control, may cause actual results and performance to differ materially from the forecasts made. Without being exhaustive, such factors include e.g. general economic and business-related conditions, including: legal issues, uncertainty relating to demand, pricing, reimbursement rules, partners' plans and forecasts, fluctuations in exchange rates, competitive factors and reliance on suppliers. An additional factor is potential side effects from the use of ALK's existing and future products, as allergy immunotherapy may be associated with allergic reactions of differing extents, durations and severities.



# Thank you for your attention

Read more: [www.alk.net](http://www.alk.net)

## Upcoming events:

- 2015 Annual Report and 2016 Outlook, 9 Feb 2016

Investor Relations:

Per Plotnikof

VP, Head of Investor Relations

Phone: +45 4574 7576

E-mail: [ppidk@alk.net](mailto:ppidk@alk.net)

